Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
In Reply: In response to Dr Jiang and colleagues,
3 independent groups have now reported that AMACR is expressed in prostate
However, as we reported, some precursor lesions, such as high-grade prostatic
intraepithelial neoplasia and atrophic lesions, also express AMACR. Jiang
et al note that still another putative precursor lesion, adenosis, may also
express AMACR. Like all putative biomarkers, AMACR may not be specific to
a single disease and should be used with caution as a tool for diagnosis.
For diagnostic purposes, AMACR should be used in combination with a basal
cell marker, as pointed out by all 3 groups.1-3
We also have observed AMACR expression in other tumor types, including colon,
breast, and melanoma.4 Therefore, AMACR
appears to be a marker for early neoplastic change but requires other markers
to help distinguish the tissue of origin.
Rubin MA, Chinnaiyan AM. α-Methylacyl Coenzyme A Racemase as a Marker for Prostate Cancer—Reply. JAMA. 2002;287(23):3080–3081. doi:10.1001/jama.287.23.3077
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: